Vaccines, Год журнала: 2022, Номер 10(11), С. 1926 - 1926
Опубликована: Ноя. 14, 2022
The world has not yet completely overcome the fear of havoc brought by SARS-CoV-2. virus undergone several mutations since its initial appearance in China December 2019. Several variations (i.e., B.1.616.1 (Kappa variant), B.1.617.2 (Delta B.1.617.3, and BA.2.75 (Omicron variant)) have emerged throughout pandemic, altering virus's capacity to spread, risk profile, even symptoms. Humanity faces a serious threat as long keeps adapting changing fundamental function evade immune system. Delta variant two escape alterations, E484Q L452R, well other mutations; most notable these is P681R, which expected boost infectivity, whereas Omicron about 60 with certain deletions insertions. 40-60% more contagious comparison Alpha variant. Additionally, AY.1 lineage, also known "Delta plus" variant, surfaced result mutation was one causes life-threatening second wave coronavirus disease 2019 (COVID-19). Nevertheless, recent variants represent reminder that COVID-19 epidemic far from ending. sparked fervor investigation on why initially appeared propagate so much rapidly than three concerns (VOCs), whether it threatening those ways, how type mutations, induce minor changes proteins, can wreck trouble. This review sheds light pathogenicity, treatments, impact vaccine efficacy
Язык: Английский
Процитировано
78Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status
Vaccines, Год журнала: 2023, Номер 11(2), С. 432 - 432
Опубликована: Фев. 13, 2023
The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the 21st century, claiming millions of lives and putting a huge burden on global economy. potential developments vaccine technologies following determination genetic sequence SARS-CoV-2 increasing efforts to bring vaccines therapeutics into market for emergency use have provided small bright spot this tragic event. Several intriguing candidates been developed using recombinant technology, engineering, other development technologies. In last decade, vast amount process has diversified towards usage viral vector-based vaccines. immune response elicited by such is comparatively higher than approved that require booster dose provide sufficient protection. non-replicating adenoviral vectors are promising carriers infectious diseases due better yield, cGMP-friendly manufacturing processes, safety, efficacy, manageable shipping, storage procedures. As April 2022, WHO total 10 around world COVID-19 (33 at least one country), among which three This review sheds light developmental summary all under authorization (EUA) or different stages management.
Язык: Английский
Процитировано
61Protein subunit vaccines: Promising frontiers against COVID-19
Journal of Controlled Release, Год журнала: 2024, Номер 366, С. 761 - 782
Опубликована: Янв. 20, 2024
Язык: Английский
Процитировано
24mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics
Vaccines, Год журнала: 2022, Номер 10(12), С. 2150 - 2150
Опубликована: Дек. 15, 2022
An unheard mobilization of resources to find SARS-CoV-2 vaccines and therapies has been sparked by the COVID-19 pandemic. Two years ago, COVID-19’s launch propelled mRNA-based technologies into public eye. Knowledge gained from mRNA technology used combat is assisting in creation treatments treat existing illnesses may avert pandemics future. Exploiting capacity create therapeutic proteins impede or a variety illnesses, including cancer, main goal quickly developing, highly multidisciplinary field biomedicine. In this review, we explore potential as vaccine using current research findings.
Язык: Английский
Процитировано
67Recent review of COVID-19 management: diagnosis, treatment and vaccination
Pharmacological Reports, Год журнала: 2022, Номер 74(6), С. 1120 - 1148
Опубликована: Окт. 10, 2022
Язык: Английский
Процитировано
55Therapeutic monoclonal antibodies for COVID-19 management: an update
Expert Opinion on Biological Therapy, Год журнала: 2022, Номер 22(6), С. 763 - 780
Опубликована: Май 23, 2022
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected more than 529 million people, and today the world is facing different mutant strains of virus, leading to increased morbidity rates, fatality surfacing re-infections. Various therapies, such as prophylactic treatments, repurposed drug convalescent plasma, polyclonal antibody therapy have been developed help combat disease 2019 (COVID-19).This review article provides insights into basic aspects monoclonal antibodies (mAbs) for COVID-19, well its advancement in terms clinical trial current approval status.Monoclonal represents most effective viable and/or prophylaxis option against shown a reduction viral load, lowering hospitalizations death rates. In countries, various mAbs are undergoing phases trials, with few them having entered III IV. Due soaring number cases worldwide, FDA given emergency mAb combinations bamlanivimab etesevimab casirivimab imdevimab.
Язык: Английский
Процитировано
54Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world
Frontiers in Immunology, Год журнала: 2022, Номер 13
Опубликована: Окт. 3, 2022
In December 2019, an outbreak emerged of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which leads to disease 2019 (COVID-19). The World Health Organisation announced the a global health emergency on 30 January 2020 and by 11 March it was declared pandemic. spread severity took heavy toll overburdening system, particularly since there were no available drugs against SARS-CoV-2. With immediate worldwide effort, communication, sharing data, large amounts funding, researchers pharmaceutical companies immediately fast-tracked vaccine development in order prevent disease, hospitalizations death. A number vaccines quickly approved for use, vaccination rollouts put place. However, due several individuals being hesitant vaccinations many poorer countries not having access vaccines, multiple SARS-CoV-2 variants that distinct from original variant. Uncertainties related effectiveness various new as well specific-side effects have remained concern. Despite these uncertainties, fast-track approval, manufacturing at scale, effective distribution COVID-19 remain topmost priorities around world. Unprecedented efforts made developers/researchers healthcare staff, played major role distributing shots provided protection and/or reduced severity, deaths, even with delta omicron variants. Fortunately, those who become infected, appears protect hospitalisation, fatality COVID-19. Herein, we analyse ongoing studies platforms saved deaths
Язык: Английский
Процитировано
49mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Vaccines, Год журнала: 2023, Номер 11(3), С. 507 - 507
Опубликована: Фев. 22, 2023
mRNA vaccines take advantage of the mechanism that our cells use to produce proteins. Our proteins based on knowledge contained in DNA; each gene encodes a unique protein. The genetic information is essential, but cannot it until molecules convert into instructions for producing specific vaccinations provide ready-to-use constructing BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) both are newly approved mRNA-based COVID-19 have shown excellent protection efficacy. In total, there five more vaccine candidates under different phases clinical development. This review specifically focused covering its development, mechanism, aspects.
Язык: Английский
Процитировано
33Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants
Vaccines, Год журнала: 2023, Номер 11(2), С. 374 - 374
Опубликована: Фев. 6, 2023
Accurate identification at an early stage of infection is critical for effective care any infectious disease. The “coronavirus disease 2019 (COVID-19)” outbreak, caused by the virus “Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)”, corresponds to current and global pandemic, characterized several developing variants, many which are classified as variants concern (VOCs) “World Health Organization (WHO, Geneva, Switzerland)”. primary diagnosis made using either molecular technique RT-PCR, detects parts viral genome’s RNA, or immunodiagnostic procedures, identify proteins antibodies generated host. As demand RT-PCR test grew fast, inexperienced producers joined market with innovative kits, increasing number laboratories diagnostic field, rendering results increasingly prone mistakes. It difficult determine how outcomes one unnoticed result could influence decisions about patient quarantine social isolation, particularly when patients themselves health providers. development point-of-care testing helps in rapid in-field disease, such can also be used a bedside monitor mapping progression patients. In this review, we have provided readers available techniques their pitfalls detecting emerging VOCs SARS-CoV-2, lastly, discussed AI-ML- nanotechnology-based smart SARS-CoV-2 detection.
Язык: Английский
Процитировано
32COVID-19 and vaccination: myths vs science
Expert Review of Vaccines, Год журнала: 2022, Номер 21(11), С. 1603 - 1620
Опубликована: Авг. 18, 2022
Introduction Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed since the inception of disease 2019 (COVID-19) in December 2019, at unprecedented speed. However, these rapidly raised many questions related to efficacy and safety different communities across globe. Various hypotheses regarding COVID-19 its were generated, them also answered with scientific evidence. Still, there are myths/misinformation vaccines, which create hesitancy for vaccination, must be addressed critically achieve success battle pandemic.Area Covered The development anti-SARS-CoV-2 COVID-19, their efficacy, relating presented.Expert Opinion In this pandemic, we seen a global collaborative effort researchers, governments, industry, supported by billions dollars funding, allowed far more quickly than past. Vaccines go through rigorous testing, analysis, evaluations clinical settings prior approval, even if they approved emergency use. Despite myths, vaccination represents an important strategy get back normality.
Язык: Английский
Процитировано
34